Early and hereditary breast cancer: advances in risk stratification and imaging approaches.

IF 4.2 2区医学 Q2 ONCOLOGY

Therapeutic Advances in Medical Oncology Pub Date : 2025-09-22 eCollection Date: 2025-01-01 DOI:10.1177/17588359251349677

Viviana Cortiana, Shreevikaa Kannan, Harshitha Vallabhaneni, Jade Gambill, Soumiya Nadar, Vraj Jigar Kumar Rangrej, Chandler H Park, Yan Leyfman

{"title":"Early and hereditary breast cancer: advances in risk stratification and imaging approaches.","authors":"Viviana Cortiana, Shreevikaa Kannan, Harshitha Vallabhaneni, Jade Gambill, Soumiya Nadar, Vraj Jigar Kumar Rangrej, Chandler H Park, Yan Leyfman","doi":"10.1177/17588359251349677","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer (BC) remains a leading global health challenge, characterized by significant heterogeneity that complicates its detection, diagnosis, and management. The integration of imaging biomarkers and radiomics into clinical workflows has revolutionized early detection, risk stratification, and personalized treatment strategies. Established modalities, such as mammography and magnetic resonance imaging, in conjunction with biomarkers like hormone receptor status, continue to play a pivotal role in guiding therapeutic decisions. Simultaneously, advancements in radiomics and artificial intelligence (AI) have enabled the extraction and analysis of high-dimensional imaging data, offering novel insights into tumor biology and predicting treatment outcomes. This review explores the synergy of imaging biomarkers, radiomics, and AI, emphasizing their potential to transform BC care through enhanced precision and optimized patient outcomes.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251349677"},"PeriodicalIF":4.2000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454969/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359251349677","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Breast cancer (BC) remains a leading global health challenge, characterized by significant heterogeneity that complicates its detection, diagnosis, and management. The integration of imaging biomarkers and radiomics into clinical workflows has revolutionized early detection, risk stratification, and personalized treatment strategies. Established modalities, such as mammography and magnetic resonance imaging, in conjunction with biomarkers like hormone receptor status, continue to play a pivotal role in guiding therapeutic decisions. Simultaneously, advancements in radiomics and artificial intelligence (AI) have enabled the extraction and analysis of high-dimensional imaging data, offering novel insights into tumor biology and predicting treatment outcomes. This review explores the synergy of imaging biomarkers, radiomics, and AI, emphasizing their potential to transform BC care through enhanced precision and optimized patient outcomes.

Abstract Image

查看原文本刊更多论文

早期和遗传性乳腺癌：风险分层和成像方法的进展。

乳腺癌（BC）仍然是一个主要的全球健康挑战，其特点是显著的异质性，使其检测、诊断和管理复杂化。将成像生物标志物和放射组学整合到临床工作流程中，彻底改变了早期检测、风险分层和个性化治疗策略。现有的方法，如乳房x光检查和磁共振成像，结合激素受体状态等生物标志物，继续在指导治疗决策中发挥关键作用。同时，放射组学和人工智能（AI）的进步使高维成像数据的提取和分析成为可能，为肿瘤生物学和预测治疗结果提供了新的见解。本综述探讨了成像生物标志物、放射组学和人工智能的协同作用，强调了它们通过提高精度和优化患者预后来改变BC护理的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Medical Oncology ONCOLOGY-

CiteScore

8.20

自引率

2.00%

发文量

160

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).